Imago BioSciences Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Imago BioSciences şirketinin toplam hissedar öz sermayesi $172.6M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $186.5M ve $13.8M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$178.41m
Eşitlik	US$172.62m
Toplam yükümlülükler	US$13.84m
Toplam varlıklar	US$186.46m

Son finansal sağlık güncellemeleri

Imago BioSciences (NASDAQ:IMGO) Is In A Good Position To Deliver On Growth Plans

Nov 08

Here's Why We're Not Too Worried About Imago BioSciences' (NASDAQ:IMGO) Cash Burn Situation

Jul 26

Companies Like Imago BioSciences (NASDAQ:IMGO) Are In A Position To Invest In Growth

Apr 12

We're Not Very Worried About Imago BioSciences' (NASDAQ:IMGO) Cash Burn Rate

Dec 08

Recent updates

Imago BioSciences (NASDAQ:IMGO) Is In A Good Position To Deliver On Growth Plans

Nov 08

Imago BioSciences GAAP EPS of -$0.41 beats by $0.09

Aug 12

Here's Why We're Not Too Worried About Imago BioSciences' (NASDAQ:IMGO) Cash Burn Situation

Jul 26

Companies Like Imago BioSciences (NASDAQ:IMGO) Are In A Position To Invest In Growth

Apr 12

We're Not Very Worried About Imago BioSciences' (NASDAQ:IMGO) Cash Burn Rate

Dec 08

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: IMGO 'nin kısa vadeli varlıkları ( $182.0M ) kısa vadeli yükümlülüklerini ( $13.8M ) aşıyor.

Uzun Vadeli Yükümlülükler: IMGO un uzun vadeli yükümlülüğü bulunmamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: IMGO borçsuzdur.

Borcun Azaltılması: IMGO son 5 yıldır borcu bulunmamaktadır.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: IMGO şirketinin mevcut serbest nakit akışına göre 3 yıldan fazla bir süre için yeterli nakit pistine sahip olduğu belirtiliyor.

Tahmini Nakit Akışı: IMGO serbest nakit akışı her yıl % 54.8 2.1 yıl yetecek nakit akışına sahip olacaktır.

Imago BioSciences Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Imago BioSciences (NASDAQ:IMGO) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not Too Worried About Imago BioSciences' (NASDAQ:IMGO) Cash Burn Situation

Companies Like Imago BioSciences (NASDAQ:IMGO) Are In A Position To Invest In Growth

We're Not Very Worried About Imago BioSciences' (NASDAQ:IMGO) Cash Burn Rate

Recent updates

Imago BioSciences, Inc.(NasdaqGS:IMGO) dropped from NASDAQ Composite Index

Merck Sharp & Dohme Corp. completed the acquisition of Imago BioSciences, Inc. (NasdaqGS:IMGO).

Chief Financial Officer exercised options to buy US$1.3m worth of stock.

Imago BioSciences, Inc. Announces First Participant Dosed in Investigator-Sponsored Phase 2 Study of Bomedemstat in Combination with Ruxolitinib in Myelofibrosis

CEO & Director notifies of intention to sell stock

Imago BioSciences, Inc. Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis at ASH 2022

Iimago Biosciences, Inc. Announces First Participant Dosed in Investigator-Sponsored Phase 1 Study of Bomedemstat in Combination with Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia

Merck & Co., Inc. (NYSE:MRK) entered into a definitive agreement to acquire Imago BioSciences, Inc. (NasdaqGS:IMGO) for $ billion $1.2 billion.

Price target increased to US$35.67

Merck & Co., Inc. (NYSE:MRK) entered into a definitive agreement to acquire Imago BioSciences, Inc. (NasdaqGS:IMGO) for $ billion $1.2 billion.

Price target decreased to US$33.00

Imago BioSciences (NASDAQ:IMGO) Is In A Good Position To Deliver On Growth Plans

Price target decreased to US$33.00

Imago BioSciences, Inc. Appoints Hsiangyi Chiang as Principal Accounting Officer

Chief Financial Officer notifies of intention to sell stock

Senior VP of Chemistry exercised options and sold US$204k worth of stock

Imago BioSciences GAAP EPS of -$0.41 beats by $0.09

Here's Why We're Not Too Worried About Imago BioSciences' (NASDAQ:IMGO) Cash Burn Situation

Imago BioSciences, Inc. Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis at EHA 2022

Imago Biosciences, Inc Announces First Participant Dosed in Investigator-Sponsored Study of Bomedemstat in Combination with Atezolizumab in Small Cell Lung Cancer

Imago Biosciences Inc. Announces Completion of Enrollment in Phase 2 Clinical Study of Bomedemstat in Essential Thrombocythemia

Companies Like Imago BioSciences (NASDAQ:IMGO) Are In A Position To Invest In Growth

COO & Interim CFO exercised options and sold US$153k worth of stock

Senior VP of Chemistry exercised options and sold US$115k worth of stock

Insider exercised options and sold US$254k worth of stock

Imago BioSciences, Inc. Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis at ASH 2021

We're Not Very Worried About Imago BioSciences' (NASDAQ:IMGO) Cash Burn Rate

Chief Financial Officer Matthew Plunkett has left the company

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin